Gonococcal antimicrobial susceptibility surveillance in Europe 2009
Since 2009, the European Centre for Disease Prevention and Control has coordinated the enhanced surveillance of sexually transmitted infections in Europe.
Gonococcal antimicrobial susceptibility surveillance in Europe – 2010
In 2010, 21 EU/EEA Member States participated in the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), testing a total of 1766 isolates.
Gonococcal antimicrobial susceptibility surveillance in Europe, 2015
The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) follows a decentralised and centralised testing model. In 2015, 24 EU/EEA Member States participated in Euro-GASP, 17 through decentralised testing.
Gonorrhoea strains across Europe becoming more susceptible to main treatment options
According to test results from the annual European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), resistance levels to the main antimicrobials used for treatment of gonorrhoea infection have seen an encouraging decrease since 2010.
EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
Gonococcal antimicrobial susceptibility surveillance in Europe, 2012
This report summarises the surveillance results for Neisseria gonorrhoeae antimicrobial susceptibility in the EU/EEA. In 2012, 20 EU/EEA Member States participated in Euro-GASP.
Molecular typing of Neisseria gonorrhoeae – a study of 2013 isolates
This report describes the second molecular typing survey of N. gonorrhoeae across the EU/EEA and provides recent information on NG-MAST STs/Gs and genotypes based on WGS circulating in 21 EU/EEA Member States.
Understanding drug-resistant gonorrhoea: an ECDC whole genome sequencing study
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens? The first study of this kind within an international surveillance programme for sexually transmitted infections shows distribution of drug-resistant gonorrhoea strains across Europe.
3rd Meeting of the Hepatitis B and C Network
On the third meeting of the Hepatitis B and C Network national focal points and experts discussed the enhanced surveillance programme for hepatitis B and C across Europe and explored ways of improving it.